Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort
Translational Research · 2024-11 · 273 · 137-147
DOI: 10.1016/j.trsl.2024.08.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2024-11. Verfasst von Marjolein F Lansbergen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology…. Hauptthemen laut MEDLINE: Leucovorin, Oxaliplatin, Irinotecan, Fluorouracil. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 MSCA, Horizon 2020 Framework Programme, ZonMw.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at metastatic stage and typically treated with fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX). Few patients benefit from this treatment. Molecular subtypes are prognostic in particularly resectable PDAC and might predict treatment response. This study aims to correlate molecular subtypes in metastatic PDAC with FOLFIRINOX responses using real-world data, providing assistance in counselling patients. We collected 131 RNA-sequenced metastatic biopsies and applied a network-based meta-analysis using published PDAC classifiers. Subsequent survival analysis was performed using the most suitable classifier. For validation, we developed an immunohistochemistry (IHC) classifier using GATA6 and keratin-17 (KRT17), and applied it to 86 formalin-fixed paraffin-embedded samples of advanced PDAC. Lastly, GATA6 knockdown models were generated in PDAC organoids and cell lines. We showed that the PurIST classifier was the most suitable classifier. With this classifier, classical tumors had longer PFS and OS than basal-like tumors (PFS: 216 vs. 78 days, p = 0.0002; OS: 251 vs. 195 days, p = 0.049). The validation cohort showed a similar trend. Importantly, IHC GATA6low patients had significantly shorter survival with FOLFIRINOX (323 vs. 746 days, p = 0.006), but no difference in non-treated patients (61 vs. 54 days, p = 0.925). This suggests that GATA6 H-score predicts therapy response. GATA6 knockdown models did not lead to increased FOLFIRINOX responsiveness. These data suggest a predictive role for subtyping (transcriptomic and GATA6 IHC), though no direct causal relationship was found between GATA6 expression and chemoresistance. GATA6 immunohistochemistry should be seamlessly added to current diagnostics and integrated into upcoming clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Amsterdam UMC, l…
- Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Cancer Center Am…
- Cancer Center Amsterdam, Amsterdam, the Netherlands; Amsterdam UMC, location University of Amsterdam, Pathology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
- Amsterdam UMC, location University of Amsterdam, Medical Oncology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Förderung
- Horizon 2020 MSCA
- Horizon 2020 Framework Programme
- ZonMw
Zitieren
APA
Lansbergen, M. F., Dings, M. P. G., Manoukian, P., Fariña, A., Waasdorp, C., Hooijer, G. K. J., Verheij, J., Koster, J., Zwijnenburg, D. A., Wilmink, J. W., Medema, J. P., Dijk, F., van Laarhoven, H. W. M., & Bijlsma, M. F. (2024). Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Translational Research, 273, 137-147. https://doi.org/10.1016/j.trsl.2024.08.002
Vancouver
Lansbergen MF, Dings MPG, Manoukian P, Fariña A, Waasdorp C, Hooijer GKJ, et al. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Translational Research. 2024;273:137-147. doi:10.1016/j.trsl.2024.08.002
BibTeX
@article{Lansbergen2024,
author = {Lansbergen, Marjolein F and Dings, Mark P G and Manoukian, Paul and Fariña, Arantza and Waasdorp, Cynthia and Hooijer, Gerrit K J and Verheij, Joanne and Koster, Jan and Zwijnenburg, Danny A and Wilmink, Johanna W and Medema, Jan Paul and Dijk, Frederike and van Laarhoven, Hanneke W M and Bijlsma, Maarten F},
title = {Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort},
journal = {Translational Research},
year = {2024},
volume = {273},
pages = {137--147},
doi = {10.1016/j.trsl.2024.08.002}
}
EUVIMED